INmune Bio Statistics
Total Valuation
INmune Bio has a market cap or net worth of $46.66 million. The enterprise value is $26.94 million.
| Market Cap | 46.66M |
| Enterprise Value | 26.94M |
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
INmune Bio has 26.59 million shares outstanding. The number of shares has increased by 22.40% in one year.
| Current Share Class | 26.59M |
| Shares Outstanding | 26.59M |
| Shares Change (YoY) | +22.40% |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | 11.28% |
| Owned by Institutions (%) | 20.43% |
| Float | 22.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.29 |
| P/TBV Ratio | 2.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.24, with a Debt / Equity ratio of 0.08.
| Current Ratio | 4.24 |
| Quick Ratio | 4.11 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -168.78% and return on invested capital (ROIC) is -65.43%.
| Return on Equity (ROE) | -168.78% |
| Return on Assets (ROA) | -52.61% |
| Return on Invested Capital (ROIC) | -65.43% |
| Return on Capital Employed (ROCE) | -211.89% |
| Weighted Average Cost of Capital (WACC) | 9.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.98M |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.92% in the last 52 weeks. The beta is 0.98, so INmune Bio's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | -41.92% |
| 50-Day Moving Average | 1.56 |
| 200-Day Moving Average | 1.55 |
| Relative Strength Index (RSI) | 48.36 |
| Average Volume (20 Days) | 723,639 |
Short Selling Information
The latest short interest is 2.38 million, so 8.97% of the outstanding shares have been sold short.
| Short Interest | 2.38M |
| Short Previous Month | 3.07M |
| Short % of Shares Out | 8.97% |
| Short % of Float | 10.77% |
| Short Ratio (days to cover) | 1.63 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -26.78M |
| Pretax Income | -41.60M |
| Net Income | -41.60M |
| EBITDA | -43.29M |
| EBIT | -43.29M |
| Earnings Per Share (EPS) | -$1.61 |
Balance Sheet
The company has $21.36 million in cash and $1.51 million in debt, with a net cash position of $19.85 million or $0.75 per share.
| Cash & Cash Equivalents | 21.36M |
| Total Debt | 1.51M |
| Net Cash | 19.85M |
| Net Cash Per Share | $0.75 |
| Equity (Book Value) | 19.62M |
| Book Value Per Share | 0.74 |
| Working Capital | 17.43M |
Cash Flow
In the last 12 months, operating cash flow was -$19.16 million and capital expenditures -$1.04 million, giving a free cash flow of -$20.20 million.
| Operating Cash Flow | -19.16M |
| Capital Expenditures | -1.04M |
| Depreciation & Amortization | 136,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -20.20M |
| FCF Per Share | -$0.76 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
INmune Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.40% |
| Shareholder Yield | -22.40% |
| Earnings Yield | -88.91% |
| FCF Yield | -43.18% |
Analyst Forecast
The average price target for INmune Bio is $7.00, which is 298.86% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.00 |
| Price Target Difference | 298.86% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 694.34% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
INmune Bio has an Altman Z-Score of -6.61 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.61 |
| Piotroski F-Score | 2 |